How big is MDxHealth SA?

As of Jun 18, MDxHealth SA has a market capitalization of 97.51 million, with net sales of 94.51 million and a net profit of -38.77 million over the latest four quarters. Shareholder's funds are 14.84 million, and total assets are 157.33 million.

As of Jun 18, MDxHealth SA has a market capitalization of 97.51 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 94.51 million, while the sum of net profit for the same period is -38.77 million.<BR><BR>As of Dec 24, the shareholder's funds amount to 14.84 million, and total assets are reported at 157.33 million.

What does MDxHealth SA do?

MDxHealth SA is a Belgium-based healthcare company specializing in molecular diagnostics for cancer treatment, with recent net sales of $24 million and a market cap of $97.51 million. The company reported a net profit of -$9 million as of March 2025.

Overview:<BR>MDxHealth SA is a Belgium-based multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 24 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -9 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 97.51 Million (Micro Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 1.89 <BR>Return on Equity: -649.58% <BR>Price to Book: 16.34 <BR><BR>Contact Details:<BR>Address: CAP Business Center, Rue d'Abhooz 31, HERSTAL None: 4040 <BR>Tel: 32 4 2577021 <BR>Fax: 32 4 2597875 <BR>Website: https://mdxhealth.com/

Who are in the management team of MDxHealth SA?

As of March 2022, the management team of MDxHealth SA includes Non-Executive Independent Chairman Mr. Mark Shaffar, CEO and Director Mr. Michael McGarrity, and Non-Executive Directors Mr. Rudi Marien, Mr. Jan Pensaert, Mme. Ruth Devenyns, and Mr. Walter Narajowski. They oversee the company's strategic direction and governance.

As of March 2022, the management team of MDxHealth SA includes the following individuals:<BR><BR>- Mr. Mark Shaffar, who serves as the Non-Executive Independent Chairman of the Board.<BR>- Mr. Michael McGarrity, who is the Chief Executive Officer and a Director.<BR>- Mr. Rudi Marien, who is a Non-Executive Director.<BR>- Mr. Jan Pensaert, who is also a Non-Executive Director.<BR>- Mme. Ruth Devenyns, who serves as a Non-Executive Independent Director.<BR>- Mr. Walter Narajowski, who is a Non-Executive Independent Director. <BR><BR>This team is responsible for overseeing the company's strategic direction and governance.

Should I buy, sell or hold MDxHealth SA?

Is MDxHealth SA technically bullish or bearish?

As of September 11, 2025, MDxHealth SA shows a bullish technical trend with strong weekly indicators, despite mixed monthly signals, and has significantly outperformed the S&P 500 year-to-date with a return of 64.56%.

As of 11 September 2025, the technical trend for MDxHealth SA has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The Bollinger Bands are bullish on both weekly and monthly time frames. Daily moving averages also indicate a bullish stance. However, the weekly RSI is bearish, and the KST shows a bullish weekly signal but a bearish monthly signal. Dow Theory reflects a mildly bullish outlook on both weekly and monthly time frames. <BR><BR>In terms of performance, MDxHealth has significantly outperformed the S&P 500 across various periods, with a year-to-date return of 64.56% compared to the S&P 500's 12.22%, and a one-year return of 51.75% versus 17.14%. Overall, the current technical stance is bullish, supported by strong weekly indicators despite some mixed signals in the monthly data.